Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)Takashi Seto, Kazuhiko Nakagawa, Seiji Niho et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 50
First‐line pembrolizumab vs chemotherapy in metastatic non‐small‐cell lung cancer: KEYNOTE‐024 Japan subset*Miyako Satouchi, Katsuyuki Hotta, Kaname Nosaki et al.|Cancer Science|2021Cited by 18
LBA55 WJOG @Be study: A phase II study of atezolizumab (atez) with bevacizumab (bev) for non-squamous (sq) non-small cell lung cancer (NSCLC) with high PD-L1 expressionTakashi Seto, Kazuhiko Nakagawa, Kaname Nosaki et al.|Annals of Oncology|2020Cited by 7
TRUST-II: A global phase II study for taletrectinib in <i>ROS1</i> fusion–positive lung cancer and other solid tumors.Misako Nagasaka, Yuichiro Ohe, Sai‐Hong Ignatius Ou et al.|Journal of Clinical Oncology|2022Cited by 4